Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain.

Dermatology reports·2026
Same author

Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis.

Blood·2026
Same author

Increasingly Reversible Na/Cl<sub>2</sub> and Li/Cl<sub>2</sub> Batteries.

Journal of the American Chemical Society·2026
Same author

Barriers to effective first-line treatment for women with iron deficiency.

Expert review of hematology·2026
Same author

Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds.

Blood advances·2026
Same author

The Prevalence of Fibromyalgia in the General Population and At-Risk Subpopulations: A Systematic Review and Meta-Analysis.

Anesthesia and analgesia·2026

Related Experiment Video

Updated: Feb 25, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.6K

Immunotherapy: Who Is Eligible?

Daniel Wang1, Jill Gilbert1, Young J Kim2

  • 1Department of Medicine, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

Otolaryngologic Clinics of North America
|July 31, 2017
PubMed
Summary
This summary is machine-generated.

Immunotherapy with immune checkpoint inhibitors offers new hope for recurrent or metastatic head and neck cancer, improving outcomes. This review details breakthroughs and future directions for patient selection and treatment considerations.

Keywords:
Checkpoint inhibitorsImmunotherapyNivolumabPD-1/PD-L1 blocking antibodiesPembrolizumabRecurrent metastatic head & neck carcinoma

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K

Related Experiment Videos

Last Updated: Feb 25, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.6K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K

Area of Science:

  • Oncology
  • Immunology

Background:

  • Recurrent and/or metastatic head and neck cancer (HNC) traditionally has a poor prognosis.
  • Conventional treatments offer limited efficacy for advanced HNC stages.

Purpose of the Study:

  • To review major breakthroughs in understanding immunotherapy for HNC.
  • To outline future directions in HNC immunotherapy research.
  • To guide clinicians in patient selection and treatment considerations for immunotherapy in HNC.

Main Methods:

  • Literature review of key studies and clinical trials.
  • Analysis of current immunotherapy approaches in HNC.
  • Discussion of emerging trends and challenges.

Main Results:

  • Immune checkpoint inhibitors (ICIs) demonstrate significant potential to improve clinical outcomes in HNC.
  • Understanding immunotherapy mechanisms is crucial for optimizing treatment efficacy.
  • Advances in immunotherapy are shifting the treatment paradigm for advanced HNC.

Conclusions:

  • Immunotherapy, particularly ICIs, represents a promising therapeutic strategy for advanced HNC.
  • Further research is needed to refine patient selection and treatment protocols.
  • Personalized approaches incorporating immunotherapy are essential for improving survival in HNC patients.